Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nabil Adra

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in OncologyEdward M Schaeffer, Sandy Srinivas, Nabil Adra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2026
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026Daniel E Spratt, Sandy Srinivas, Nabil Adra, et al.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
European Urology|January 30, 2023
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER StudyNoah M Hahn, Michael A O'Donnell, Jason A Efstathiou, et al.
Journal of the National Cancer Institute|August 11, 2023
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary TumorsTalal El Zarif, Amin H Nassar, Gregory R Pond, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in OncologyEdward M Schaeffer, Sandy Srinivas, Nabil Adra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2026
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026Daniel E Spratt, Sandy Srinivas, Nabil Adra, et al.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
European Urology|January 30, 2023
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER StudyNoah M Hahn, Michael A O'Donnell, Jason A Efstathiou, et al.
Journal of the National Cancer Institute|August 11, 2023
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary TumorsTalal El Zarif, Amin H Nassar, Gregory R Pond, et al.
Pageof 10